Book contents
- Frontmatter
- Contents
- List of contributors
- Introduction
- Section 1 Global health, definitions and descriptions
- Section 2 Global health ethics, responsibilities and justice: some central issues
- Section 3 Analyzing some reasons for poor health
- Section 4 Shaping the future
- 20 The Health Impact Fund: how to make new medicines accessible to all
- 21 Biotechnology and global health
- 22 Food security and global health
- 23 International taxation
- 24 Global health research: changing the agenda
- 25 Justice and research in developing countries
- 26 Values in global health governance
- 27 Poverty, distance and two dimensions of ethics
- 28 Teaching global health ethics
- 29 Towards a new common sense: the need for new paradigms of global health
- Index
- References
21 - Biotechnology and global health
Published online by Cambridge University Press: 01 March 2011
Book contents
- Frontmatter
- Contents
- List of contributors
- Introduction
- Section 1 Global health, definitions and descriptions
- Section 2 Global health ethics, responsibilities and justice: some central issues
- Section 3 Analyzing some reasons for poor health
- Section 4 Shaping the future
- 20 The Health Impact Fund: how to make new medicines accessible to all
- 21 Biotechnology and global health
- 22 Food security and global health
- 23 International taxation
- 24 Global health research: changing the agenda
- 25 Justice and research in developing countries
- 26 Values in global health governance
- 27 Poverty, distance and two dimensions of ethics
- 28 Teaching global health ethics
- 29 Towards a new common sense: the need for new paradigms of global health
- Index
- References
Summary
Introduction
As the branch of science concerned with the application of biological processes for industrial, health and agricultural purposes, biotechnology joins nutritional science and biomedical engineering as a major application of science and technology for improving human health. But every new technology poses ethical issues. What are the current and potential benefits of the technology, and what are the risks? How can the profit motive be harnessed for technology development, while keeping humanitarian technologies affordable? How much should be invested in developing the technology, and how much in scaling up existing techniques?
This chapter shines a light on these ethical issues by describing how biotechnology might be employed to improve global health, and discussing factors to consider when thinking about risks and implementation. We begin with the example of smallpox and vaccines, and continue on to biotechnologies for applications such as diagnostics, micronutrients, clean water, bioremediation, drug delivery systems and therapies. (It is important to note that the potential longer-term health applications of biotechnology extend far beyond the current and near-term applications which are the focus of this chapter.)
The eradication of smallpox through the advent of vaccination is one of the great success stories of modern medicine and public health (Barquet & Domingo, 1997; Andre, 2002). Although the process of exposing a healthy person to infected materials, known as variolation, was commonly practiced in China, India and Turkey before the mid-fifteenth century, a significant proportion of those treated died from serious infection.
- Type
- Chapter
- Information
- Global Health and Global Health Ethics , pp. 251 - 260Publisher: Cambridge University PressPrint publication year: 2011
References
, , et al. (2009). Small but tenacious: South Africa's health biotech sector. Nature Biotechnology 27, 427–445.CrossRefGoogle ScholarPubMed
(2002). Vaccinology: past achievements, present roadblocks and future promise. Vaccine 21, 593–595.CrossRefGoogle Scholar
, , et al. (2008). Vaccination greatly reduces disease, disability, death and inequity worldwide. WHO Bulletin 86(2), 81–160.Google ScholarPubMed
& (1997). Smallpox: the triumph over the most terrible of the ministers of death. Annals of Internal Medicine 127(8), 635–642.CrossRefGoogle Scholar
(2006). The Wealth of Networks: How Social Production Transforms Markets and Freedom. New Haven, CT:Yale University Press.Google Scholar
& (Eds.) (2008). Global Catastrophic Risks. Oxford:Oxford University Press.
, & (2005). Facilitating humanitarian access to pharmaceutical and agricultural innovation. Innovation Strategy Today 1(3), 203–216.Google Scholar
(2009). Global Health Innovators: A Collection of Case Studies. Washington, DC: BIO Ventures for Global Health Report.
, , , & (2010). India's billion dollar biotech in the developing world. Nature Biotechnology 28, 783.CrossRefGoogle Scholar
, , et al. (2002). Top ten biotechnologies for improving health in developing countries. Nature Genetics 32, 229–232.CrossRefGoogle ScholarPubMed
, , et al. (2007). Grand challenges in chronic non-communicable diseases. Nature 450, 494–496.CrossRefGoogle ScholarPubMed
, , et al. (2002). Biotechnology and bioremediation: successes and limitations. Applied Microbiology and Biotechnology 59, 143–152.Google ScholarPubMed
, , et al. (2007). India's health biotech sector at a crossroads. Nature Biotechnology 25(4), 403–417.CrossRefGoogle Scholar
, , et al. (2008). Chinese health biotech and the billion-patient market. Nature Biotechnology 26, 37–53.CrossRefGoogle ScholarPubMed
, & (2009). A business plan to help the “global south” in its fight against neglected diseases. Health Affairs 28(6), 1760–1773.CrossRefGoogle ScholarPubMed
& (2009). Access: How do Good Health Technologies get to Poor People in Poor Countries?Cambridge, MA: Harvard University Press.Google Scholar
(2006). Biotechnology Unzipped: Promises and Realities. (2nd edn.) Washington, DC:Joseph Henry Press.Google Scholar
, , et al. (Eds.) (2002). The Precautionary Principle in the 20th Century: Late Lessons from Early Warnings. London: Earthscan Publications.
, & (2009). Improving health R&D financing for developing countries: a menu of innovative policy options. Health Affairs 28(4), 974–985.CrossRefGoogle Scholar
(2008). The Gridlock Economy: How Too Much Ownership Wrecks Markets, Stops Innovation, and Costs Lives. New York: Basic Books.Google Scholar
(2007). What led to the Nigerian boycott of the polio vaccination campaign?PLoS Medicine 4(3), e73.CrossRefGoogle ScholarPubMed
& (2007). Freedom to Innovate: Biotechnology in Africa's Development. Report of the High-Level African Panel on Modern Biotechnology, African Union and NEPAD (New Partnership for Africa's Development).
, , et al. (Eds.) (2007). Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices. MIHR (Oxford), PIPRA (Davis, CA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro) and bioDevelopments-International Institute (Ithaca, NY).
, & (2005). 4 million neonatal deaths: When? Where? Why?Lancet 365(9462), 891–900.CrossRefGoogle ScholarPubMed
& (2004). Millions Saved: Proven Successes in Global Health. Washington, DC:Center for Global Development.Google Scholar
, & (2004). The introduction of new vaccines into developing countries, III: The role of intellectual property. Vaccine 22(5–6), 786–792.CrossRefGoogle ScholarPubMed
(2009). World's largest malaria vaccine trial now underway in seven African countries. www.malariavaccine.org/files/1122009_RTSSP3PressRelease_FINAL.pdf. (Accessed on January 15, 2010, archived at www.webcitation.org/5mnFJzDkk on December 15, 2010).
& (2007). A visual dashboard for moving health technologies from “lab to village”. Journal of Medical Internet Research 9(4), e32.CrossRefGoogle Scholar
(2009). Investing in the Future: A United Call to Action on Vitamin and Mineral Deficiencies. Micronutrient Initiative. www.unitedcalltoaction.org/documents/Investing_in_the_future.pdf (Accessed January 15, 2010, archived at www.webcitation.org/5n1h45iUy on January 15, 2010).
(2006). McSurgery: a man who saved 2.4 million eyes. Wall Street Journal (August 5, 2006). www.aravind.org/tribute/A%20Man%20Who%20Saved%202.4%20Million%20Eyes.pdf (Accessed December 8, 2009, archived at www.webcitation.org/5lrXwNm8B on December 8, 2009).Google Scholar
(Ed.). (2009). The Development Agenda: Global Intellectual Property and Developing Countries. Oxford:Oxford University Press.
, , et al. (2005). Improving the nutritional value of Golden Rice through increased pro-vitamin A content. Nature Biotechnology 23, 482–487.CrossRefGoogle ScholarPubMed
, , et al. (2008). Brazilian health biotech – fostering crosstalk between public and private sectors. Nature Biotechnology 26, 627–644.CrossRefGoogle ScholarPubMed
, , et al. (2005). Nanotechnology and the developing world. PLoS Medicine 2(5), e97.CrossRefGoogle ScholarPubMed
(2008). Pichia power: India's biotech industry puts unconventional yeast to work. Chemistry and Biology 15(3), 201–202.CrossRefGoogle ScholarPubMed
(2003). Redesigning Humans: Choosing our Genes, Changing our Future. Boston, MA: Houghton Mifflin.Google Scholar
(2009). AIDS Epidemic Update: November 2009. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). Geneva: UNAIDS.
& (1999). A new paradigm for world agriculture: meeting human needs – productive, sustainable, nutritious. Field Crop Research 60, 1–10.CrossRefGoogle Scholar
(WHO) (2002). Genomics and World Health: Report of the Advisory Committee on Health Research. Geneva:World Health Organization.Google Scholar
, , et al. (2006). Microfluidic diagnostic technologies for global public health. Nature 442, 412–418.CrossRefGoogle ScholarPubMed
, & (2008). Point-of-care diagnostics for global health. Annual Review of Biomedical Engineering 10, 107–144.CrossRefGoogle ScholarPubMed